Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 2:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 3,504 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adult-Onset Diabetes Mellitus Clear all
Completed Phase 1 Interventional

Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus

NCT01082120
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AZD1656, Pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2010 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Phase 2 Interventional

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

NCT06628362
View directory record Official record
Conditions
Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
Interventions
Placebo, Enicepatide
Drug
Lead sponsor
Carmot Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
52
States / cities
Birmingham, Alabama • Guntersville, Alabama • Yuma, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 13, 2026, 2:14 AM EDT
Terminated Phase 4 Interventional Results available

Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery

NCT01765270
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Cardiovascular Disease
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
45 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Birmingham, Alabama • Huntsville, Alabama • Fort Smith, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated May 29, 2015 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

INcreasing Veteran EngagemeNT to Prevent Diabetes (INVENT)

NCT03403231
View directory record Official record
Conditions
Prediabetes
Interventions
INVENT Secure Messaging Intervention
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Up to 75 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Not applicable Interventional

A Continuous Glucose Monitor Based Insulin Bolus Calculator

NCT05229445
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
continuous glucose monitor based insulin bolus calculator
Device
Lead sponsor
Welldoc
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 13, 2026, 2:14 AM EDT
Completed No phase listed Observational

Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction

NCT06914141
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
Tirzepatide, Semaglutide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
28,118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 13, 2026, 2:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Impact of Community Health Workers on Adherence to Therapy for Non-Communicable Chronic Disease in Chiapas, Mexico

NCT02549495
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715

NCT00365781
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
ISIS 113715
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2007 · Synced Oct 13, 2026, 2:14 AM EDT
Terminated Not applicable Interventional

Study of a Home Delivered Meal Program on Obese Elderly African American Subjects With Type 2 Diabetes Mellitus (DM)

NCT00743756
View directory record Official record
Conditions
Obesity, Diabetes
Interventions
home-delivered meals, diabetes education for 12 months
Dietary Supplement · Behavioral
Lead sponsor
Emory University
Other
Eligibility
65 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Phase 1 Interventional

Study of Subcutaneous Doses of HIP2B in Subjects With Type 2 Diabetes Mellitus Treated With Metformin

NCT01933256
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
HIP2B, Placebo
Drug
Lead sponsor
CureDM
Industry
Eligibility
30 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Genetic Risk and Health Coaching for Type 2 Diabetes and Coronary Heart Disease

NCT01884545
View directory record Official record
Conditions
Coronary Heart Disease, Susceptibility to, 5, Prediabetic State
Interventions
Health coaching, Genetic risk counseling, Standard risk assessment
Behavioral · Genetic
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Fairfield, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Phase 1 Interventional

To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Metformin

NCT00774553
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
AZD1656, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2010 · Synced Oct 13, 2026, 2:14 AM EDT
Active, not recruiting Phase 4 Interventional

DIALYSIS-TIR Study

NCT06042153
View directory record Official record
Conditions
Type 2 Diabetes, End Stage Renal Disease on Dialysis
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
Chapel Hill, North Carolina • Dallas, Texas • Irving, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Not applicable Interventional

Can Whey Protein Improve Glycemic Control in Type 2 Diabetes?

NCT01925248
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hyperglycemia
Interventions
Whey protein, Placebo group
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
25 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Phase 2 Interventional

A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy

NCT01169090
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
SK-0403, Placebo, Sitagliptin
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
40
States / cities
Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Phase 3 Interventional Results available

A Study in Adults With Type 2 Diabetes

NCT01421459
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2963016, Lantus, OAMs
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
28
States / cities
Montgomery, Alabama • Brooksville, Florida • Fort Lauderdale, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Phase 3 Interventional

Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus

NCT00519142
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
placebo for mitiglinide, mitiglinide
Drug
Lead sponsor
Elixir Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
57
States / cities
Glendale, Arizona • Greenbrae, California • La Jolla, California + 54 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2009 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Not applicable Interventional

Provider-Initiated Regular Remote Interventions for Optimal Type 2 Diabetes Care

NCT01920256
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Remote, personalized type 2 diabetes care., Usual Endocrine care.
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 13, 2026, 2:14 AM EDT
Terminated Phase 3 Interventional

Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin

NCT00998686
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
dutogliptin, sitagliptin
Drug
Lead sponsor
Phenomix
Industry
Eligibility
18 Years to 85 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
23
States / cities
Montgomery, Alabama • Tempe, Arizona • Anaheim, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2010 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Phase 3 Interventional

Lifestyle Interventions for Expectant Mothers (LIFE-Moms Phoenix) - Phoenix

NCT01812694
View directory record Official record
Conditions
Obesity, Diet Therapy, Diabetes Type 2
Interventions
Enhanced standard care, Intensive lifestyle intervention
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

DM-BOOST Para Latinx: a Diabetes Mellitus Program Using Behavioral Economics to Optimize Outreach and Self-management Support With Technology for Latinx Patients

NCT05583877
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Diabetes BOOST, Usual Care
Behavioral
Lead sponsor
Daniel Amante
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Phase 1Phase 2 Interventional

Comparison of Postprandial Glucose Control Associated With BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500

NCT02212951
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
BIOD-531, Humalog Mix 75/25, Humulin R U-500
Drug
Lead sponsor
Biodel
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Phase 4 Interventional

Early Diabetes Intervention Program

NCT01470937
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Acarbose, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
25 Years to 80 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 11, 2011 · Synced Oct 13, 2026, 2:14 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus

NCT02863419
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
40
States / cities
Birmingham, Alabama • Los Alamitos, California • San Diego, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 13, 2026, 2:14 AM EDT